Final Analysis of the Phase I/II Study of CC-486 (Oral Azacitidine) Maintenance Therapy after Allogeneic Stem Cell Transplantation (Allo-SCT) in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)
Year: 2017
Type: article
Study design: Clinical Trial
Source: Blood
Institutions: University Hospitals Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Western Reserve University, The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Fred Hutch Cancer Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Celgene (United States), Queen Elizabeth Hospital Birmingham
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2944822648